Press Releases Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
5.865 ^USD	-0.42%		+17.07%	+108.72%

Apr. 11	Black Diamond Therapeutics, Inc. Announces Board and Committee Changes	CI
Apr. 08	Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Apr. 24	GL
Black Diamond Therapeutics Announces Changes to Board of Directors	Apr. 11	GL
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting	Apr. 07	GL
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting	Apr. 07	AQ
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences	Apr. 03	GL
Black Diamond: Q4 Earnings Snapshot	Mar. 12	AQ
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Mar. 12	GL
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Mar. 12	AQ
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024	Mar. 05	GL
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	Feb. 28	GL
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	Feb. 28	AQ
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones	Jan. 04	GL
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones	Jan. 04	AQ
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM	Dec. 13	GL
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences	Nov. 07	GL
Black Diamond Therapeutics : November 2023 Corporate Presentation	Nov. 06	PU
Black Diamond: Q3 Earnings Snapshot	Nov. 06	AQ
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 06	GL
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535	23-10-14	AQ
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535	23-10-14	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Press Releases

Filters